^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CRTC1-MAML2 fusion

i
Other names: MAML2, Mastermind Like Transcriptional Coactivator 2 , Mastermind-Like Protein 2, MAM3, MLL-MAML2, MAM-3, MAML2, CRTC1, CREB Regulated Transcription Coactivator 1, TORC1, Mucoepidermoid Carcinoma Translocated Protein 1, CREB-Regulated Transcription Coactivator 1, TORC-1, WAMTP1, MECT1, Transducer Of Regulated CAMP Response Element-Binding Protein (CREB) 1, Transducer Of Regulated CAMP Response Element-Binding Protein 1, Transducer Of Regulated CAMP Response Element-Binding Protein, Mucoepidermoi
Entrez ID:
Associations
Trials
over1year
Long read sequencing identifies complex structural variant landscape and recurrent TERT rearrangements in mucoepidermoid carcinoma. (PubMed, Oral Oncol)
Critically, TERT knockdown in NCI-H292, a cell line with TERT promoter rearrangement, reduced clonogenic cell survival, supporting a critical role of this gene in MEC tumorigenesis. Overall, our data suggest that complex chromothripsis rearrangement mechanisms drive the formation of structural variation in CRTC1::MAML2 fusion positive and negative tumors and reveal highly recurrent structural variation driving TERT rearrangement in MEC.
Journal
|
CRTC1 (CREB Regulated Transcription Coactivator 1) • MAML2 (Mastermind Like Transcriptional Coactivator 2) • MYBL1 (MYB Proto-Oncogene Like 1)
|
TERT amplification • TERT rearrangement • CRTC1-MAML2 fusion
over1year
The clinical outcome, pathologic spectrum, and genomic landscape for 454 cases of salivary mucoepidermoid carcinoma. (PubMed, NPJ Precis Oncol)
Specific genetic events (in TP53 and FBXW7) with CRTC1::MAML2 fusion superimposed might be associated with unfavorable prognosis. This study provides new insights into precision therapeutic strategies for MEC.
Clinical data • Journal
|
TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • BAP1 (BRCA1 Associated Protein 1) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • EWSR1 (EWS RNA Binding Protein 1) • CRTC1 (CREB Regulated Transcription Coactivator 1) • MAML2 (Mastermind Like Transcriptional Coactivator 2)
|
TP53 mutation • CDKN2A mutation • MET mutation • CRTC1-MAML2 fusion
2years
Genomics and tumor microenvironment of breast mucoepidermoid carcinoma based on whole-exome and RNA sequencing. (PubMed, Diagn Pathol)
Overall, we first analyzed the genomics and tumor microenvironment of breast mucoepidermoid carcinoma and proposed our hypothesis that although MECs arising in the breast resemble their salivary gland counterparts phenotypically, our findings indicate that breast MECs probably resemble invasive breast carcinomas at the genetic level and immune cell infiltration levels. More cases and in deep research need to be done to further understand this rare carcinoma.
Retrospective data • Journal • Tumor mutational burden
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TMB (Tumor Mutational Burden) • MUC4 (Mucin 4, Cell Surface Associated) • CRTC1 (CREB Regulated Transcription Coactivator 1) • MAML2 (Mastermind Like Transcriptional Coactivator 2)
|
ER positive • HER-2 amplification • CRTC1-MAML2 fusion
over2years
Genetic and Immunohistochemical Profiling of Mammary Hidradenoma and Comparison to Mucoepidermoid Carcinoma. (PubMed, Mod Pathol)
Mucinous and glandular/luminal cells were identified in significantly more mammary hidradenomas than non-mammary lesions. The findings provide insight into the pathogenesis of MAML2-rearranged neoplasms of the breast, underscore the overlapping genetic features of MEC and hidradenoma, and highlight similarities to their extramammary counterparts.
Journal • Tumor mutational burden
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • TMB (Tumor Mutational Burden) • SOX10 (SRY-Box 10) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1) • MUC4 (Mucin 4, Cell Surface Associated) • TP63 (Tumor protein 63) • CRTC1 (CREB Regulated Transcription Coactivator 1) • MAML2 (Mastermind Like Transcriptional Coactivator 2)
|
MUC4 expression • CRTC1-MAML2 fusion
almost3years
The Challenge of "Monomorphic" Mucoepidermoid Carcinoma-Report of a Rare Case with Pure Spindle-Clear Cell Morphology. (PubMed, Head Neck Pathol)
Mucoepidermoid carcinoma featuring a uniform ("monomorphic") population of neoplastic cells is a novel observation. A confident diagnosis of mucoepidermoid carcinoma can be made upon detection of the CRTC1/3::MAML2 fusion. Our case increases the spectrum of histopathological appearances that mucoepidermoid carcinoma may display.
Journal
|
CRTC1 (CREB Regulated Transcription Coactivator 1) • MAML2 (Mastermind Like Transcriptional Coactivator 2)
|
CRTC1-MAML2 fusion
3years
A radiolucent rarity - primary intraosseous mucoepidermoid carcinoma of the posterior mandible: From radiographic incidental finding to molecular pathological diagnosis (PubMed, Swiss Dent J)
The presented case report emphasizes the central role of private dental practices in the early detection of oral malignancies. These should always be considered in the differential diagnosis of cystic lesions.
Journal
|
CRTC1 (CREB Regulated Transcription Coactivator 1) • MAML2 (Mastermind Like Transcriptional Coactivator 2)
|
CRTC1-MAML2 fusion
over3years
Tight junction gene expression in salivary gland tumors. (PubMed, Pathol Res Pract)
Increased CLDN5 expression was associated with submandibular gland tumors. This study demonstrated differential expressions of genes encoding tight junction constituent proteins and their associations with tumor characteristics, suggesting their potential future role as diagnostic and prognostic markers.
Journal
|
TJP1 (Tight Junction Protein 1) • CLDN5 (Claudin 5) • CRTC1 (CREB Regulated Transcription Coactivator 1) • F11R (F11 Receptor) • MAML2 (Mastermind Like Transcriptional Coactivator 2) • OCLN (Occludin)
|
CRTC1-MAML2 fusion
over3years
Management and outcome of parotid mucoepidermoid carcinoma by histological grade: A 21-year review. (PubMed, Laryngoscope Investig Otolaryngol)
Expression of the CRTC1-MAML2 fusion gene could be helpful in not only the assessment of grade but the prediction of recurrence. 4.
Review • Journal
|
CRTC1 (CREB Regulated Transcription Coactivator 1) • MAML2 (Mastermind Like Transcriptional Coactivator 2)
|
CRTC1-MAML2 fusion
almost4years
Thymic Mucoepidermoid Carcinoma: A Clinicopathologic and Molecular Study. (PubMed, Am J Surg Pathol)
Of note, none of the patients with CRTC1-MAML2 fusion-positive tumors died during the follow-up. In conclusion, the clinicopathologic and molecular findings of thymic MEC presented here are expected to contribute to the management of this rare tumor.
Journal
|
CRTC1 (CREB Regulated Transcription Coactivator 1) • MAML2 (Mastermind Like Transcriptional Coactivator 2)
|
CRTC1-MAML2 fusion
almost4years
Establishment of a patient-derived mucoepidermoid carcinoma cell line with the CRTC1-MAML2 fusion gene. (PubMed, Mol Clin Oncol)
The results predicted that AREG-EGFR signaling, which is required for tumor growth and survival, might be activated in the cell line in a cell-autonomous manner. As AREG expression is associated with EGFR-targeted drug resistance, this cell line might assist with the identification of novel strategies for MEC treatment.
Preclinical • Journal
|
AREG (Amphiregulin) • CRTC1 (CREB Regulated Transcription Coactivator 1) • MAML2 (Mastermind Like Transcriptional Coactivator 2)
|
AREG expression • CRTC1-MAML2 fusion
over4years
Salivary mucoepidermoid carcinoma: Histological variants, grading systems, CRTC1/3-MAML2 fusions, and clinicopathological features. (PubMed, Histopathology)
Recognition of the histological diversity of MEC, its clinicopathological features, and its associations with CRTC1/3-MAML2 fusions is helpful for an accurate diagnosis of this carcinoma.
Clinical • Journal
|
CRTC1 (CREB Regulated Transcription Coactivator 1) • MAML2 (Mastermind Like Transcriptional Coactivator 2)
|
CRTC1-MAML2 fusion
over4years
MAML2 gene rearrangement, fusion patterns and clinicopathological characteristics in primary pulmonary mucoepidermoid carcinoma (PubMed, Zhonghua Bing Li Xue Za Zhi)
RNAseq confirms that CRTC1/3-MAML2 is the main fusion pattern in PMEC, suggesting that MAML2 fusion transcription may be an important driving factor of PMEC. MAML2 rearrangement/fusion and related clinicopathological characteristics are associated with good prognosis.
Clinical • Journal
|
CRTC1 (CREB Regulated Transcription Coactivator 1) • MAML2 (Mastermind Like Transcriptional Coactivator 2)
|
CRTC1-MAML2 fusion